Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGEND001 cell therapy · 1 trial · 1 indication
DLCO is considered a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.
| Arm | Type | Description |
|---|---|---|
| REGEND001 cell therapy | EXPERIMENTAL | REGEND001 cell therapy |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| REGEND001 cell therapy | DRUG | Transplantation of the cell product |
| Placebo | DRUG | Transplantation of Placebo |
Inclusion Criteria: * Male or female, aged 40 to 75 at the time of signing informed consent. * Diagnosed with COPD according to the 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD). * The ratio of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)FEV1/FVC is...
REGEND001 cell therapy is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD), specifically in patients with a diffusion capacity defect. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
REGEND001 cell therapy is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical research on this investigational therapy for Chronic Obstructive Pulmonary Disease.
REGEND001 cell therapy is in Phase 2 clinical development. It is an investigational therapy for Chronic Obstructive Pulmonary Disease and has not been approved by the FDA or other regulatory agencies. The therapy remains under clinical investigation to evaluate its safety and efficacy.
REGEND001 cell therapy has one completed clinical trial, identified as NCT05638776, titled "Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy." This Phase 2 trial enrolled 58 participants in China and was placebo-controlled, though it was not double-blinded.
REGEND001 cell therapy is a distinct investigational therapy being developed specifically for Chronic Obstructive Pulmonary Disease with a diffusion capacity defect. No alternative names for this therapy have been reported. It is currently in Phase 2 clinical trials and has not been approved for commercial use.